Xencor Inc

XNCR

Equity

ISIN US98401F1057 / Valor 22585567

NASDAQ (2024-09-16)

USD 21.15-1.49%

Xencor Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Xencor Inc is a biopharmaceutical company that focuses on expanding the therapeutic boundaries of antibody and cytokine drugs. Utilizing its XmAb® protein engineering platform, the company is developing a diverse pipeline of drug candidates optimized for the treatment of cancer and autoimmune disorders. With over 20 programs in clinical testing and numerous others in preclinical development, Xencor is dedicated to advancing innovative treatments for patients in need. Additionally, the company has three XmAb medicines currently on the market through partnerships with other pharmaceutical companies.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

Xencor Inc. reported revenue of $44.7 million for the fourth quarter of 2023, a significant increase from the $21.6 million reported in the same quarter of 2022. For the full year 2023, revenue was $168.3 million, up from $164.6 million in 2022.

Operating Expenses

In the fourth quarter of 2023, Xencor Inc.'s operating expenses totaled $78.3 million, compared to $64.2 million in the fourth quarter of 2022. For the full year, operating expenses were $307.0 million, up from $247.1 million in 2022, driven primarily by increased research and development costs.

Net Loss

Xencor Inc. reported a net loss of $19.1 million for the fourth quarter of 2023, compared to a net loss of $12.0 million in the same period of 2022. For the full year 2023, the net loss was $126.1 million, significantly higher than the $55.2 million net loss reported in 2022.

Cash Position

As of December 31, 2023, Xencor Inc. had cash, cash equivalents, and marketable debt securities totaling $551.5 million, compared to $580.6 million as of December 31, 2022. This decrease reflects the company's ongoing investments in its research and development programs.

Stockholders' Equity

Xencor Inc.'s total stockholders' equity was $669.1 million as of December 31, 2023, down from $727.5 million at the end of 2022. This decline is primarily due to the net losses incurred during the year.

Summarized from source with an LLMView Source

Key figures

2.22%1Y

-36.7%3Y

-41.8%5Y

Performance

48.4%1Y

44.6%3Y

50.6%5Y

Volatility